A meta-analysis of 13 randomized trials found no overall survival benefit from adding immune checkpoint inhibitors to standard care in unselected advanced ovarian cancer populations. While such approaches remain under active investigation, the pooled randomized evidence did not demonstrate a survival advantage, reinforcing the need for better biomarker-driven patient selection.